Broadcom Rises As Top AI Chip Supplier After Nvidia, Thanks To Google And Meta Partnerships: Analyst
Broadcom, the global No. 2 AI semiconductor supplier behind Nvidia, has an Overweight rating with a price target of $1,700.
Bath & Body Works To See More Comfort In Second Half Numbers With Further Improvement: Analysts
Analysts foresee Bath & Body Works' second-half performance improving, citing strength in product innovation and category expansion, despite inventory uptick in Q1 FY24.
Nvidia Has ‘Multi-Year Lead’ On AMD, Intel: Bank Of America Analyst Expects Stock To Hit $1,500 Per Share
Nvidia is "best positioned" to help the IT industry deliver AI services and has a multi-year lead over competitors, analyst says.
Stitch Fix’s Results Show ‘Green Shoots’ Emerging: Analysts Take A Look While Stock Jumps Higher
Stitch Fix reports better-than-expected Q3 results, but analysts remain cautious about declining active clients and elevated acquisition costs.
CrowdStrike Outperforms Peers Against Tough Macro In Q1, 10 Analysts Comment On ‘Top Name To Own In Security’
"We continue to be encouraged by the strength in [CrowdStrike's] underlying business," Truist Securities noted.
PVH, Parent Of Calvin Klein, Tommy Hilfiger, Impresses Analysts With Q1 Earnings Beat
PVH Corp's stock climbs after upbeat Q1 earnings report. Although revenues declined, they were broadly as expected. The company raised its FY outlook.
Lululemon Athletica Recovering From Merchandising Missteps, Says Analyst
Oppenheimer analyst Brian Nagel reiterated an Outperform rating for Lululemon Athletica with a $445 price target. Despite a 35% drop in shares post-Q4 results, Nagel remains optimistic, noting a stable EPS forecast and potential recovery from merchandising missteps.
Nvidia Maintains Lead As Key AI beneficiary, Analyst Boosts Estimates After Taiwan Event
Mizuho analyst notes Nvidia's continued growth potential with upcoming products, raising price target for Buy ratings on Nvidia, AMD, and Intel.
Structure Therapeutics’ Obesity Candidate Is ‘ Very Competitive’ To Eli Lilly’s Orforglipron, Analyst Says
Structure Therapeutics reports positive 12-week Phase 2a obesity study results for GSBR-1290, showing a 6.2% weight loss. Cantor Fitzgerald maintains an Overweight rating with a $65 target
Nvidia To Remain As A Benchmark For Computing Industry And Spur Demand, Say Analysts
Goldman Sachs analyst Toshiya Hari reiterated a Buy rating on the shares of Nvidia with a price target of $1,200. BofA Securities analyst Vivek Arya reiterated a Buy rating on the shares and raised the price target from $1,320 to $1,500.